Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Growth in 2025?
The market for drugs that modulate the sphingosine 1 phosphate receptor (S1PR) has seen robust growth in the past few years. The market value is projected to rise from $2.44 billion in 2024 to $2.60 billion in 2025, with a compound annual growth rate (CAGR) of 6.3%. The historical growth of this market can be owed to factors such as a surge in autoimmune diseases cases, increased funding for developing autoimmune drugs, wider range of indications, increased understanding of managing autoimmune diseases, and a boost in healthcare expenditure.
What Is the Forecast for the Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Size Through 2029?
The market for sphingosine 1 phosphate receptor (S1PR) modulator drugs is projected to experience substantial growth in the coming years, escalating to an impressive $3.28 billion by 2029, due to a compound annual growth rate (CAGR) of 6.0%. Driving factors for this expansion during the forecast period include a surge in demand for oral therapies as opposed to injections, an increasing occurrence of autoimmune diseases, an increase in global healthcare spending, enhanced recognition and diagnosis of diseases like multiple sclerosis, and a growing number of seniors vulnerable to autoimmune diseases. Promising trends for the forecast period encompass advancements in receptor selectivity, new indications receiving regulatory approval, the application of real-world evidence (RWE), technological progression in drug delivery, a pivot towards oral therapies, and strategic partnerships and acquisitions.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21288&type=smp
What are the Key Market Players in Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market and How They’re Evolving?
Major companies operating in the sphingosine 1 phosphate receptor (S1PR) modulator drugs market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bristol Myers Squibb Company, Novartis International AG, Biogen Inc., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Ono Pharmaceutical Co. Ltd., Actelion Pharmaceuticals Ltd., KYORIN Pharmaceutical Co. Ltd., Vanda Pharmaceuticals Inc., Celgene Corporation, Ventyx Biosciences Inc., Idorsia Pharmaceuticals Ltd., Cayman Chemical Company, Juvisé Pharmaceuticals, Priothera Limited, Arena Pharmaceuticals.
What Are the Primary Growth Drivers in the Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market?
An increase in the occurrence of autoimmune diseases is anticipated to fuel the expansion of the sphingosine 1 phosphate receptor (S1PR) modulator drugs market. Autoimmune diseases involve a scenario where the body’s immune system inadvertently damages the body’s healthy cells, leading to inflammation and harm. This increase in the prevalence of autoimmune diseases is attributed to genetic influences, environmental factors, lifestyle modifications, and enhanced diagnostic methods. Sphingosine 1-Phosphate Receptor (S1PR) modulator drugs serve as a treatment for autoimmune diseases as they regulate the migration of immune cells, thus lessening inflammation in disorders like multiple sclerosis and ulcerative colitis. To illustrate, data released by the National Center for Health Statistics (NCHS), a US-based health statistics organization, in May 2024 showed a rise in the prevalence of current asthma among adults over the age of 18 in the United States, from 8.4% in 2021 to 8.7% in 2022. Also, the rate of asthma episodes in the past year for adults in the same age bracket increased from 3.3% in 2021 to 3.7% in 2022. Hence, the growing prevalence of autoimmune diseases is catalyzing the expansion of the sphingosine 1-phosphate receptor (S1PR) modulator drugs market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21288&type=smp
What Are the Leading Segments in the Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Industry?
The sphingosine 1 phosphate receptor (S1PR) modulator drugs market covered in this report is segmented –
1) By Type: Fingolimod, Ozanimod
2) By Route Of Administration: Oral, Injectable, Topical
3) By Application: Multiple Sclerosis, Cardiovascular Diseases, Transplant Rejection
4) By End User: Hospital, Rehabilitation Centres, Retail Pharmacies
Subsegments:
1) By Fingolimod: Branded Formulations, Generic Formulations
2) By Ozanimod: Oral Capsules, Other Formulations
What Are the Key Market Trends in the Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Industry?
Leading firms in the S1PR (sphingosine 1 phosphate receptor) modulator drugs industry are honing in on novel therapies like oral treatments, to increase patient adherence, amplify the effectiveness of drugs and broaden the therapeutic applications of S1PR modulator drugs for autoimmune diseases and other associated ailments. Oral therapy involves taking these drugs as pills or tablets, presenting a convenient and non-invasive treatment method for individuals suffering from autoimmune diseases. For example, Pfizer, a pharmaceutical and biotechnology company based in the US, made the announcement in March 2022 about the positive results of the phase 3 trial of etrasimod for ulcerative colitis patients. The medication achieved its primary and key secondary endpoints, demonstrating significant progress in remission, endoscopic results, and symptom relief, thereby underscoring etrasimod’s possible role as a new therapy for moderate-to-severe ulcerative colitis. Pfizer is planning to progress regulatory submissions, bolstering its immune-inflammatory disease portfolio. This validates the company’s commitment to revolutionary healthcare solutions.
Access The Full Report Here:
What Is the Regional Outlook for the Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market?
Asia-Pacific was the largest region in the sphingosine 1 phosphate receptor (S1PR) modulator drugs market in 2024. The regions covered in the sphingosine 1 phosphate receptor (S1PR) modulator drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21288
This Report Delivers Insight On:
1. How big is the sphingosine 1 phosphate receptor (s1pr) modulator drugs market, and how is it changing globally?
2. Who are the major companies in the sphingosine 1 phosphate receptor (s1pr) modulator drugs market, and how are they performing?
3. What are the key opportunities and risks in the sphingosine 1 phosphate receptor (s1pr) modulator drugs market right now?
4. Which products or customer segments are growing the most in the sphingosine 1 phosphate receptor (s1pr) modulator drugs market?
5. What factors are helping or slowing down the growth of the sphingosine 1 phosphate receptor (s1pr) modulator drugs market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model